Citations

Showing 10 of 108083 citations.

Effect of IL-4 and IL-13 on the chemotaxis of mouse eosinophils (38.2)
Gwinn, William M., Lee, James J. , Constant, Stephanie L., Keegan, Achsah , Heller, Nicola

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S23-S23

10.4049/jimmunol.178.supp.38.2 Get It

Abstract Eosinophils are a major pathological component of the inflammatory cell infiltrate found in lungs as a result of allergic disease. They migrate into lungs in response to a variety of chemokines. The development and effector phases of the allergic response are dependent on the actions of interleukin (IL)-4 and IL-13 on a wide variety of cell types. However, how these two cytokines directly affect eosinophil signaling, function and chemotaxis is largely unknown. Using mouse eosinophils purified from IL-5 transgenic mice and a transwell migration assay, eotaxin-1 (30nM) induced eosinophil migration 6–11x over background. IL-4 alone was able to induce eosinophil migration 2x over background. More eosinophils migrated in response to eotaxin when IL-14 or IL-13 was also placed in the bottom chamber. IL-4 appeared to be more potent than IL-13. This effect was dependent upon cytokine concentration. Interestingly, when eosinophils were pretreated with IL-4 for 30 minutes prior to chemotaxis, migration to eotaxin-1 was enhanced 4-fold. However, pretreatment with IL-13 did not enhance chemotaxis to eotaxin-1. These data suggest that IL-4 and IL-13 have direct and rapid effects on the chemotactic function of eosinophils with some differences. We are investigating the mechanisms of these effects, as well as other signaling and functional responses of eosinophils to these cytokines. (AI38985 and HLT32007698)
The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology
Herrmann, Joerg , Lyon, Alexander R. , Lyon, Alexander R , López‐Fernández, Teresa

Mayo Clinic

European Heart Journal | January 2, 2023 | Volume: 44 | Issue: 5 | Pages: 348-350

10.1093/eurheartj/ehac813 | PMID 36587940 Get It

Regulation of B cell fate determination by EBF (83.7)
Medina, Kay L.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S113-S113

10.4049/jimmunol.178.supp.83.7 Get It

Abstract B cell fate specification is associated with the expression of genes encoding components of the B cell antigen receptor and the ordered rearrangement of the immunoglobulin heavy-chain locus. Accompanying activation of the early program of B lineage gene expression is the concerted repression of lineage inappropriate genes. EBF is a transcription factor expressed exclusively in the B lineage and evidence is mounting that it is the limiting factor directing the B cell fate choice. To gain insight into mechanisms of EBF directed B cell fate specification, we generated EBF−/− cell lines. The cell surface phenotype, growth factor requirements, gene expression profile, and in vivo functional capabilities of EBF−/− clonal cell lines is consistent with a lymphoid-biased multipotential progenitor. To identify and discriminate novel EBF target genes involved in B cell fate specification, we performed comparative gene expression profiling of EBF−/−, Pax-5−/−, and RAG2−/− cell lines. ANOVA analysis of variance revealed that the EBF−/− lines overexpress several genes associated with early hematopoietic differentiation and stem cell function, notably a subset of HoxA genes. Conversely, the EBF−/− cells are defective in expression of a subset of early B lineage genes including lymphocyte enhancer factor-1, LEF-1. Consistent with the deficiency in LEF-1, EBF−/− lines display elevated levels of fas and increased sensitivity to apoptosis. Taken together, these data suggest novel regulatory circuits involving EBF during B cell fate specification, including inhibition of HoxA genes and activation of the Wnt signaling pathway.
Spontaneous Inflammatory Disease in HLA-B27 Transgenic Mice Is Independent of MHC Class II Molecules: A Direct Role for B27 Heavy Chains and Not B27-Derived Peptides
Khare, Sanjay D., Bull, Michael J., Hanson, Julie A., Luthra, Harvinder S., David, Chella S.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 160 | Issue: 1 | Pages: 101-106

10.4049/jimmunol.160.1.101 Get It

Abstract Although association of HLA-B27 with human spondyloarthropathies has been known for several years, its role in disease pathogenesis is not understood. Recently, a few investigators have proposed that presentation of B27-derived peptides by MHC class II molecules may be the underlying mechanism. HLA-B27 transgenic rat and mouse models have provided a new tool for understanding the exact role of B27 in disease pathogenesis. HLA-B27 mice lacking endogenous β2-microglobulin (B27+β2mo) develop disease after they are transferred from the barrier facility to the conventional colony. This model was utilized to test the hypothesis that B27-derived peptide presented by MHC class II molecules is the cause of the disease. The MHC class II knockout gene, Aβo, was bred into our B27+β2mo mice, and disease manifestation was monitored. These mice develop spontaneous disease, demonstrating that MHC class II molecules do not play a major role in B27-related disease. Thus, the disease is not manifested by presentation of B27-derived peptides by class II molecules, since these mice are devoid of H2-A and H2-E molecules. Furthermore, in vivo treatment with mAb against the heavy chain of B27 reduced the incidence of disease in B27+β2mo mice. Our results clearly demonstrate that B27 heavy chains are directly involved in the disease process.
Induction of a Th1 Response from Th2 Polarized T Cells by Activated Dendritic Cells: Dependence on TCR:pMHC Interaction, ICAM-1, IL-12 (92.7)
Radhakrishnan, Suresh , Wiehagen, Karla R., Pulko, Vesna, Knutson, Keith L. , WIlliam, Faubion, Pease, Larry R. , Knutson, Keith L.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S163-S163

10.4049/jimmunol.178.supp.92.7 Get It

Abstract Dendritic cells (DC) are important regulators of T cell immunity. The degree of stimulation, the pattern of co-stimulatory molecules expressed, and the cytokines secreted by DC dictate the nature of the effector and memory cells generated, particularly with respect to their Th1 or Th2 phenotypes. In this report we demonstrate that addition of activated DC to spleen cultures containing established Th2 polarized CD4+ T cells was sufficient to suppress Th2 and to induce Th1 cytokines in a recall response, a phenomenon referred to as phenotype reversal. The ability of activated DC to induce phenotype reversal displayed exquisite antigen specificity. The DC activator B7-DC XAb was more than 10,000-fold more efficient at inducing phenotype reversal than the TLR agonists, CpG-ODN and Gardiquimod. Characterization of the mechanisms governing phenotype reversal revealed the requirement for cognate interaction between the TCR: pMHC complex, the expression of the co-stimulation/adhesion molecule ICAM-1, and secretion of IL-12 and IFNƒ×ƒnby the activated DC. Requirement for the co-stimulation/adhesion molecule SLAM was found to be quantitative. Thus, activation of DC, particularly by cross linking B7-DC, can modulate well established Th2 T cell responses in an antigen specific manner.
Derivation of synergistically acting, neutralizing, chimeric human-mouse anti-SEB monoclonal antibodies (47.35)
Tilahun, Mulualem E., Rajagopalan, Govindarajan , Osborne, Barbara A. , Goldsby, Richard A.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S73-S73

10.4049/jimmunol.178.supp.47.35 Get It

Abstract Staphylococcal Enterotoxin B (SEB) is a superantigen made by S. aureus. SEB can cause food poisoning and shock and its stability and ease of preparation make it a potential agent of bioterrorism. SEB-mediated activation induces T cell proliferation and secretion of cytokines. Antibodies that block the interaction between SEB and MHC or SEB and TCR, can neutralize the activating effects of SEB and provide protection against its debilitating effects. Human IVIG, a therapy for SEB intoxication is of low potency and sometimes, short supply. To surmount we have derived of mouse monoclonal antibodies that block the binding of SEB to MHC at separate and distinct sites. Combinations of these antibodies synergistically neutralize SEB mediated T cell activation. Genes encoding the VL and VH genes of synergistically neutralizing pairs of cell lines were cloned and grafted onto genes encoding either the constant region of human IgH or Igκ and transfected into SP2/0 cells. Chimeric human-mouse antibodies expressed by the transfectants were purified. Tests of these chimeric antibodies demonstrated that they were neutralizing and in combination with each other, still capable of synergistic neutralization of SEB. Supported by NIH grant # AI057652
The role of LacCer inhibitor in modulation of established Pneumocystis pneumonia (91.1)
Vuk-Pavlović, Zvezdana, Standing, Joseph E., Limper, Andrew H.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S160-S160

10.4049/jimmunol.178.supp.91.1 Get It

Abstract Pneumocystis pneumonia is caused, at least partly, by inflammatory action of β-glucan, the major component of Pneumocystis cell wall. Glucan induces release of pro-inflammatory cytokines in alveolar macrophages and lung epithelial cells. While macrophages recognize glucan mainly by dectin receptors, epithelial cells utilize membrane glycosphingolipid (GSL) lactosyl ceramide (LacCer) as glucan-binding molecule. The use of GSL inhibitors in vitro causes reduced NF-κB activation and inhibited IL-8 release in epithelial cells. To assess the impact of LacCer in lung inflammation, we treated Pneumocystis-infected mice with GSL inhibitor PDMP. The animals were immunosuppressed by GK 1.5 antibody, infected with Pneumocystis by intratracheal injection and, starting at 8 weeks post infection, treated with either 150 mg PDMP/kg of body weight - dissolved in saline, or equal volume of saline alone (daily i.p. injections for 10 days). The analysis of sacrificed animals showed that PDMP-treated mice had fewer leukocytes in the bronchoalveolar lavage fluid (BALF) than saline-treated controls with the most marked difference in the number of neutrophils. Interestingly, BALF concentrations of MIP-2 and TNF-α (determined by ELISA) did not differ between these two groups. The analysis of Pneumocystis burden in the lung, as determined by Q-PCR, showed a trend of decreased Pneumocystis-specific DNA copies in PDMP-treated animals. These results suggest that PDMP might have an impact on inflammatory response to Pneumocystis. Other GSL inhibitors are yet to be tested in similar in vivo experiments. This might lead to new options in treatment of Pneumocystis pneumonia. Supported by NIH RO1 HL62150 and Mayo
NKG2D Regulates Viral Load in the CNS During Acute Picornavirus Infection (43.37)
C, Deb, Deb, Chandra, Howe, Charles L.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S43-S43

10.4049/jimmunol.178.supp.43.37 Get It

Abstract Neurovirulent picornaviral infections are a significant health risk in developing nations. Unfortunately, the mechanisms of picornaviral clearance from the central nervous system (CNS) are less understood and therapeutic approaches are limited. We have established a mouse model of neurovirulent picornavirus infection using the Theiler’s murine encephalomyelitis virus (TMEV) which replicates during the first 12 days postinfection (dpi) primarily in the hippocampus but is cleared from the brain by 21 dpi. Intracerebral infection of TMEV triggers the early infiltration of natural killer cells (NKCs) followed by CD8+ T cells (CTLs) into the brain. We observed that both brain-infiltrating NKCs and CTLs express the NKG2D activating receptor on their surface and 50% of the the CTLs specific to the VP2121–130 viral capsid peptide also expressed NKG2D. Concomitantly, brains of infected mice expressed NKG2D ligands such as RAE-1, H-60 and MULT-1 and microglia were the cellular locus of these ligands. Importantly, systemic treatment with the NKG2D function blocking antibody CX5 resulted in a significant increase in viral load in the brain. These results suggest that activated and infected microglia stimulate NKCs and CTLs via NKG2D in a manner that restricts viral replication. NKG2D may thus serve as a potential therapeutic target to enhance viral clearance responses during CNS infection. This work was supported by a grant from the National MS Society and by Donald and Frances Herdrich.
Tumor cell lysate and adjuvant B7DC-XAb confers effective protection from two antigenically distinct melanomas (48.15)
Hanson, Michael J., Pease, Larry R. , Pavelko, Kevin D. , Hanson, Michael J

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S77-S77

10.4049/jimmunol.178.supp.48.15 Get It

Abstract Immunotherapeutic approaches to the treatment of melanoma have been hindered by the emergence of melanoma variants and relapsing tumors that are antigenically distinct and hence not recognized by memory cells. We have identified an antibody that has proven effective for the treatment of a mouse model of melanoma, B16. B7DC-XAb is an antibody that specifically binds to dendritic cells and increases their antigen uptake capabilities and their ability to activate T-cells and generates strong cytotoxic lymphocyte responses. We are using B16 tumor cell lysates along with this antibody as an adjuvant for the generation of robust and rapid CTL responses to B16 melanoma. Treatment of B16 tumor challenged mice with B7DC-XAb leads to a CTL response that recognizes an epitope from tyrosinase related protein-1. Subsequent B16-OVA tumor challenge results in a lack of protection, against this related but antigenically unique tumor. Therefore we have used tumor cell lysates in conjunction with antibody treatment in an attempt to broaden the specificity against the melanoma lines. Therapeutic treatment with B16 tumor cell lysate and B7DC-XAb leads to clearance of a 6 day established B16 tumor. Further, re-challenge 30 days later with B16-OVA is also cleared demonstrating an enhanced memory response, to this antigenically distinct tumor. Further studies will determine which antigens are responsible for initiating this response as well as those that are important for tumor clearance.
Group 2 innate lymphoid cells are present in mouse uterine tissue and may play roles in healthy pregnancy (MUC7P.763)
Bartemes, Kathleen R. , Kita, Hirohito

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 192 | Issue: Supplement_1 | Pages: 197.15-197.15

10.4049/jimmunol.192.supp.197.15 Get It

Abstract Innate lymphoid cells (ILCs) are emerging as important effector cells in innate immunity and tissue homeostasis. Group 2 ILCs (ILC2s) have been identified in organs and tissues, such as adipose tissue, small intestine, lungs and skin, where they are involved in helminth immunity, type 2 immune responses, and tissue pathology and recovery. Using flow cytometry, we identified ILC2s in mouse uteri and confirmed IL-5, but not IL-13, production in response to IL-33 both in vivo and in vitro. Furthermore, intraperitoneal administration of IL-33 induced recruitment of activated ILC2s to uteri as well as to lungs. To investigate the possibility that uterine ILC2s might play a role in maintaining a healthy pregnancy, we mated ST2-/- females (on a Balb/c background) with ST2-/-, MHC-matched Balb/c and MHC-mismatched C57B6 males (ST2 is the IL-33 receptor). Balb/c, C57B6 and Balb/c x C57B6 pairs were used as controls. Litter sizes were not significantly different among the pairings. We defined viable pups as those still alive 24 hours after parturition. Total numbers of non-viable pups, percent of litters with at least one non-viable pup and percent of non-viable pups per litter were significantly increased in ST2-/- x C57B6 pairs when compared to control pairs. Thus, IL-33-responsive ILC2s are present in murine uterine tissue and may play roles in successful reproduction.